Unknown

Dataset Information

0

Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells.


ABSTRACT: The insulin-like growth factor (IGF) system is a well-studied growth regulatory pathway implicated in breast cancer biology. Clinical trials testing monoclonal antibodies directed against the type I IGF receptor (IGF1R) in combination with estrogen receptor-? (ER) targeting have been completed, but failed to show benefits in patients with endocrine-resistant tumors compared to ER targeting alone. We have previously shown that the closely related insulin receptor (InsR) is expressed in tamoxifen-resistant (TamR) breast cancer cells. Here we examined if inhibition of InsR affected TamR breast cancer cells. InsR function was inhibited by three different mechanisms: InsR short hairpin RNA, a small InsR-blocking peptide, S961 and an InsR monoclonal antibody (mAb). Suppression of InsR function by these methods in TamR cells successfully blocked insulin-mediated signaling, monolayer proliferation, cell cycle progression and anchorage-independent growth. This strategy was not effective in parental cells likely because of the presence of IGFR /InsR hybrid receptors. Downregulation of IGF1R in conjunction with InsR inhibition was more effective in blocking IGF- and insulin-mediated signaling and growth in parental cells compared with single-receptor targeting alone. Our findings show TamR cells were stimulated by InsR and were not sensitive to IGF1R inhibition, whereas in tamoxifen-sensitive parental cancer cells, the presence of both receptors, especially hybrid receptors, allowed cross-reactivity of ligand-mediated activation and growth. To suppress the IGF system, targeting of both IGF1R and InsR is optimal in endocrine-sensitive and -resistant breast cancer.

SUBMITTER: Chan JY 

PROVIDER: S-EPMC4982805 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells.

Chan J Y JY   LaPara K K   Yee D D  

Oncogene 20160215 32


The insulin-like growth factor (IGF) system is a well-studied growth regulatory pathway implicated in breast cancer biology. Clinical trials testing monoclonal antibodies directed against the type I IGF receptor (IGF1R) in combination with estrogen receptor-α (ER) targeting have been completed, but failed to show benefits in patients with endocrine-resistant tumors compared to ER targeting alone. We have previously shown that the closely related insulin receptor (InsR) is expressed in tamoxifen-  ...[more]

Similar Datasets

| S-EPMC5089806 | biostudies-literature
| S-EPMC2879282 | biostudies-literature
| S-EPMC8281892 | biostudies-literature
| S-ECPF-GEOD-28645 | biostudies-other
| S-EPMC7450135 | biostudies-literature
| S-EPMC7299846 | biostudies-literature
| S-EPMC3788134 | biostudies-literature
| S-EPMC2875375 | biostudies-literature
| S-EPMC6389274 | biostudies-literature
| S-EPMC6434949 | biostudies-literature